Ally Financial received a Strong Buy rating at $55 from Raymond James, while EyePoint Pharmaceuticals had its target slashed 80% to $4.
1 report, 1 independent
Updated Sep 2
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Ally Financial received a Strong Buy rating at $55 from Raymond James, while EyePoint Pharmaceuticals had its target slashed 80% to $4.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Ally Financial
American financial services company
-
EyePoint Pharmaceuticals (United Kingdom)
company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery
Nothing else this week.
-
TD Cowen
American investment bank